Pfizer

Health Care Pharmaceuticals New York City, New York Last filing Feb 26, 2026 · FY2025

                    Revenue
                    FY2025
                
$62.6B
                    3y CAGR -14.8%
                    
                    P4
                    
                    -1.6%
                    
                    Net income
                    FY2025
                
$7.8B
                    Net margin +12.4%
                    
                    P49
                    
                    -3.2%
                    
                    Total assets
                    FY2025
                
$208.0B
                    ROA +3.7%
                    
                    P29
                    
                    -2.3%
                    
                    Operating cash flow
                    FY2025
                
$11.7B
                    FCF margin +14.5%
                    
                    P51
                    
                    -8.2%

19 yrs · FY2007–FY2025 8 filed · 0 derived · 1 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

31 accounts · 10 years

Total assets $208.0B

Total liabilities $121.4B

Shareholders equity $86.5B

Account	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Assets
Cash and Cash Equivalents	1.8%	1.6%	4.8%	0.4%	2.4%	4.3%	2.5%	2.8%	2.6%	4.9%
Short Term Investments	19.9%	30.5%	16.5%	22.1%	35.8%	24.9%	16.5%	43.3%	35.5%	28.9%
Accounts Receivable	19.0%	18.0%	19.4%	10.8%	14.1%	18.9%	16.9%	19.7%	15.6%	15.6%
Inventory	17.0%	17.1%	17.1%	8.9%	11.1%	19.2%	16.0%	18.4%	14.4%	12.8%
Other Current Assets	10.8%	11.9%	14.9%	8.5%	9.9%	16.4%	11.5%	38.1%	10.2%	11.5%
Total Current Assets	68.6%	79.1%	72.8%	50.7%	73.4%	83.7%	63.4%	122.3%	78.3%	73.7%
Property,Plant and Equipment	30.9%	28.9%	31.8%	16.1%	18.3%	33.2%	27.0%	32.8%	26.4%	25.2%
Goodwill	113.9%	107.7%	113.8%	50.8%	60.5%	118.3%	113.3%	130.8%	106.5%	103.1%
Intangible Assets	85.9%	87.1%	109.0%	42.9%	30.9%	67.9%	68.3%	86.2%	92.8%	99.7%
Long Term Investments	2.6%	3.5%	6.3%	14.9%	26.5%	48.3%	38.9%	6.8%	13.4%	13.5%
Deferred Tax Assets	15.5%	13.6%	6.2%	6.6%	4.1%	5.7%	4.1%	4.7%	3.5%	3.4%
Other Noncurrent Assets	15.4%	15.4%	20.9%	13.0%	9.4%	10.9%	8.6%	6.9%	6.1%	6.3%
Total Assets	332.4%	334.8%	381.2%	194.7%	222.7%	368.0%	322.7%	390.5%	327.3%	325.6%
Liabilities
Accounts Payable	8.4%	8.9%	11.3%	6.7%	6.9%	10.3%	8.2%	11.4%	8.9%	8.6%
Accrued Liabilities	14.6%	14.4%	12.6%	7.2%	8.4%	15.0%	11.2%	14.0%	8.9%	9.2%
Deferred Revenue	1.3%	2.4%	4.5%	2.5%	3.8%	—	—	—	—	—
Current Portion of Long Term Debt	5.0%	10.9%	17.4%	2.9%	2.8%	6.4%	31.3%	21.6%	18.9%	20.2%
Other Current Liabilities	29.8%	31.0%	34.5%	22.3%	30.7%	30.2%	21.4%	31.0%	21.2%	20.9%
Total Current Liabilities	59.1%	67.6%	80.3%	41.6%	52.5%	61.8%	72.1%	78.0%	57.9%	58.9%
Long Term Debt	99.1%	89.6%	104.1%	32.6%	44.3%	88.6%	69.5%	80.6%	63.8%	59.4%
Deferred Tax Liabilities	3.8%	3.3%	1.1%	1.0%	0.4%	9.7%	10.8%	9.1%	7.4%	58.2%
Other Noncurrent Liabilities	32.5%	35.2%	45.7%	24.9%	30.5%	56.4%	48.7%	66.6%	61.4%	35.0%
Total Liabilities	194.0%	196.3%	230.4%	100.1%	128.0%	216.6%	201.0%	234.3%	190.6%	211.6%
Equity
Common Stock	0.8%	0.8%	0.8%	0.5%	0.6%	1.1%	0.9%	1.1%	0.9%	0.9%
Additional Paid In Capital	151.0%	147.1%	155.5%	90.7%	111.4%	211.6%	168.9%	211.3%	160.4%	156.5%
Retained Earnings	183.1%	183.5%	198.7%	124.2%	127.2%	230.9%	188.7%	219.4%	162.3%	135.9%
Treasury Stock	183.8%	180.4%	192.2%	112.6%	137.0%	264.8%	214.1%	248.9%	170.2%	159.7%
Accumulated Other Comprehensive Income	-12.9%	-12.3%	-13.4%	-8.2%	-7.3%	-27.9%	-22.5%	-27.6%	-17.7%	-20.9%
Total Stockholders Equity	138.2%	138.6%	149.5%	94.6%	95.0%	150.9%	122.0%	155.3%	135.7%	112.7%
Noncontrolling Interest	0.5%	0.5%	0.5%	0.3%	0.3%	0.6%	0.6%	0.9%	0.7%	0.6%
Total Liabilitiesand Equity	332.6%	335.4%	380.3%	194.9%	223.3%	368.0%	323.7%	390.5%	326.9%	324.9%

Income Statement

Revenue, expense, and profitability

13 accounts · 10 years

Revenue $62.6B

Operating income Not reported

Net income $7.8B

Account	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
IncomeStatement
Revenues Total Revenue	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Expenses Cost of Revenue	25.7%	28.1%	41.9%	33.9%	37.9%	20.7%	19.7%	22.0%	21.4%	23.3%
Expenses Research and Development	16.7%	17.0%	17.9%	11.3%	12.7%	22.4%	16.7%	19.0%	14.6%	14.9%
Expenses Selling,General and Administrative	22.0%	23.2%	24.8%	13.5%	15.6%	27.7%	27.7%	30.9%	28.2%	28.1%
Other Income Expense Other Income/expense	-23.6%	-19.2%	-13.6%	-6.9%	-3.8%	-11.2%	-1.6%	-19.3%	-12.4%	-17.8%
Other Income Expense Income Before Tax	12.0%	12.6%	1.8%	34.3%	29.9%	17.9%	34.2%	8.8%	23.4%	15.8%
Income Tax Income Tax Expense	-0.4%	-0.0%	-1.9%	3.3%	2.3%	1.1%	2.7%	-0.7%	-17.2%	2.1%
net Income Other Items Below Tax	-0.0%	-0.0%	-0.1%	-0.0%	-0.6%	6.2%	-0.0%	17.9%	-0.1%	-0.0%
net Income net Income	12.4%	12.6%	3.6%	31.0%	27.0%	22.9%	31.4%	27.3%	40.6%	13.7%
net Income Comprehensive Income	12.1%	12.8%	4.1%	28.6%	26.3%	23.0%	30.7%	22.5%	43.8%	10.8%
Earnings Per Share Basic Eps	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings Per Share Diluted Eps	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings Per Share Weighted Average Shares Diluted	9.1%	9.0%	9.6%	5.7%	7.0%	13.4%	11.0%	14.6%	11.5%	11.7%

Cash Flow Statement

Operating, investing, and financing flows

20 accounts · 10 years

Operating cash flow $11.7B

Investing cash flow $-1.4B

Financing cash flow $-10.3B

Account	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
CashFlow
Operating Activities net Income	12.5%	12.7%	3.6%	31.0%	27.1%	21.9%	31.0%	27.4%	40.6%	13.7%
Operating Activities Depreciation and Amortization	10.5%	11.0%	10.6%	5.0%	6.4%	11.2%	11.1%	15.1%	11.9%	10.9%
Operating Activities Stock Based Compensation	1.3%	1.4%	0.9%	0.9%	1.5%	1.8%	1.3%	2.3%	1.6%	1.3%
Operating Activities Deferred Income Taxes	-3.4%	-3.3%	-5.8%	-3.7%	-5.3%	-3.8%	0.5%	-6.9%	-24.9%	-1.3%
Operating Activities Changes In Operating Assets and Liabilities	-8.6%	-4.8%	-3.6%	-5.6%	15.8%	-0.7%	-7.5%	-0.8%	2.5%	0.2%
Operating Activities Other Non Cash Items	6.4%	3.1%	8.9%	1.3%	-5.9%	10.0%	-1.8%	19.7%	0.1%	5.9%
Operating Activities net Cash From Operating Activities	18.7%	20.0%	14.6%	28.9%	40.1%	34.4%	24.3%	38.8%	32.0%	30.7%
Investing Activities Capital Expenditures	-4.2%	-4.6%	-6.6%	-3.2%	-3.3%	-5.3%	-4.0%	-4.9%	-3.7%	-3.5%
Investing Activities Business Acquisitions	-11.1%	0.0%	-72.9%	-22.7%	0.0%	0.0%	-21.0%	0.0%	-1.9%	-34.8%
Investing Activities Purchases of Investments	-23.4%	-16.2%	-52.4%	-37.9%	-48.6%	-34.4%	-13.6%	-33.0%	-34.5%	-45.4%
Investing Activities Proceeds From Sale of Investments	40.5%	20.0%	69.3%	44.9%	34.6%	28.2%	18.2%	58.4%	26.4%	77.0%
Investing Activities Other Investing Activities	-4.0%	4.9%	8.4%	3.2%	-10.3%	1.3%	12.7%	-9.4%	4.7%	-8.2%
Investing Activities net Cash From Investing Activities	-2.2%	4.2%	-54.2%	-15.6%	-27.7%	-10.2%	-7.6%	11.1%	-9.0%	-14.7%
Financing Activities Proceeds From Debt	15.5%	14.0%	59.4%	3.8%	1.2%	41.9%	41.3%	21.3%	26.1%	34.9%
Financing Activities Repayment of Debt	-14.3%	-21.2%	-4.3%	-7.1%	-2.5%	-62.5%	-29.3%	-19.6%	-30.6%	-24.2%
Financing Activities Dividends Paid	-15.6%	-14.9%	-15.5%	-8.9%	-10.7%	-20.1%	-15.5%	-19.5%	-14.6%	-13.9%
Financing Activities Other Financing Activities	-2.0%	-4.8%	4.2%	-0.6%	-0.1%	17.7%	4.3%	-5.4%	1.5%	-6.8%
Financing Activities net Cash From Financing Activities	-16.5%	-26.9%	43.8%	-14.7%	-12.1%	-23.0%	-16.4%	-50.1%	-25.4%	-17.5%
Cash Reconciliation Effect of Exchange Rate On Cash	0.1%	-0.1%	-0.1%	-0.2%	-0.1%	-0.0%	-0.1%	-0.3%	0.1%	-0.4%
Cash Reconciliation net Change In Cash	0.1%	-2.8%	4.1%	-1.5%	0.2%	1.1%	0.2%	-0.5%	-2.4%	-2.0%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 10 years

Ratio	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Profitability
Gross margin	+74.3%	+71.9%	+58.1%	+66.1%	+62.1%	+79.3%	+80.3%	+78.0%	+78.6%	+76.7%
Operating margin	—	—	—	—	—	—	—	—	—	—
Net margin	+12.4%	+12.6%	+3.6%	+31.0%	+27.0%	+22.9%	+31.4%	+27.3%	+40.6%	+13.7%
FCF margin	+14.5%	+15.5%	+8.0%	+25.7%	+36.7%	+29.1%	+20.4%	+33.9%	+28.3%	+27.2%
Growth
Revenue CAGR (3y)	-14.8%	-7.8%	+12.4%	+25.0%	+25.8%	-7.3%	-0.7%	-5.8%	+1.9%	+0.8%
Returns
ROE	+9.0%	+9.1%	+2.4%	+32.8%	+28.5%	+15.2%	+25.8%	+17.6%	+29.9%	+12.1%
ROA	+3.7%	+3.8%	+0.9%	+15.9%	+12.1%	+6.2%	+9.7%	+7.0%	+12.4%	+4.2%
ROIC	—	—	—	—	—	—	—	—	—	—
Liquidity
Current ratio	1.16x	1.17x	0.91x	1.22x	1.40x	1.35x	0.88x	1.57x	1.35x	1.25x
Quick ratio	0.35x	0.29x	0.30x	0.27x	0.31x	0.37x	0.27x	0.29x	0.31x	0.35x
Leverage
D/E	1.40x	1.42x	1.54x	1.06x	1.35x	1.44x	1.65x	1.51x	1.40x	1.88x
Interest coverage	—	—	—	—	—	—	—	—	—	—
Efficiency
Asset turnover	0.30x	0.30x	0.26x	0.51x	0.45x	0.27x	0.31x	0.26x	0.31x	0.31x
Cash conversion cycle	+192d	+172d	+122d	+63d	+93d	+226d	+207d	+187d	+152d	+123d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Pfizer

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history